Advertisement
Advertisement
BNGO
Bionano Genomics, Inc. Common Stock
1.20
USDSponsored
+0.01
+0.84%
Aug 12, 16:00 UTC -4
Closed
After-Market
1.18
-0.02
-1.92%
BNGO Earnings Reports
Positive Surprise Ratio
BNGO beat 13 of 32 last estimates.
41%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$8.75M
/-$0.49
Implied change from Q2 26 (Revenue/ EPS)
+7.06%
/-23.44%
Implied change from Q3 25 (Revenue/ EPS)
+18.73%
/-69.18%
Bionano Genomics, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, BNGO reported earnings of -0.64 USD per share (EPS) for Q2 26, beating the estimate of -0.69 USD, resulting in a 8.40% surprise. Revenue reached 8.17 million, compared to an expected 7.63 million, with a 7.14% difference. The market reacted with a +2.59% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 8.75 million USD, implying an decrease of -23.44% EPS, and increase of 7.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Longeveron Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.17
Actual
-$0.19
Surprise
-6.44%
Artelo Biosciences, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-Actual
-$0.89
Surprise
-
Kailera Therapeutics, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.76
Actual
-$1.09
Surprise
-42.48%
Forte Biosciences, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.89
Actual
-$0.97
Surprise
-8.25%
Allogene Therapeutics, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.17
Actual
-$0.13
Surprise
+25.50%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.57
Actual
-$0.41
Surprise
+28.22%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.45
Surprise
-20.16%
Humacyte, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.16
Surprise
-56.86%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.21
Surprise
-5.58%
Spruce Biosciences, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$5.91
Actual
-$6.68
Surprise
-12.88%
FAQ
What were Bionano Genomics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Bionano Genomics, Inc. Common Stock reported EPS of -$0.64, beating estimates by 8.4%, and revenue of $8.17M, 7.14% above expectations.
How did the market react to Bionano Genomics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 2.59%, changed from $1.16 before the earnings release to $1.19 the day after.
When is Bionano Genomics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Bionano Genomics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Bionano Genomics, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $8.75M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement